- Home
- GTEC vs GRCE Comparison
GTEC vs GRCE Comparison
Compare GTEC & GRCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GTEC
- GRCE
- Stock Information
- Founded
- GTEC 2006
- GRCE 2002
- Country
- GTEC United States
- GRCE United States
- Employees
- GTEC N/A
- GRCE N/A
- Industry
- GTEC Industrial Machinery/Components
- GRCE
- Sector
- GTEC Industrials
- GRCE
- Exchange
- GTEC Nasdaq
- GRCE NYSE
- Market Cap
- GTEC 18.2M
- GRCE 32.1M
- IPO Year
- GTEC N/A
- GRCE N/A
- Fundamental
- Price
- GTEC $1.34
- GRCE $2.18
- Analyst Decision
- GTEC
- GRCE Strong Buy
- Analyst Count
- GTEC 0
- GRCE 1
- Target Price
- GTEC N/A
- GRCE $12.00
- AVG Volume (30 Days)
- GTEC 122.8K
- GRCE 35.4K
- Earning Date
- GTEC 04-15-2025
- GRCE 02-13-2025
- Dividend Yield
- GTEC N/A
- GRCE N/A
- EPS Growth
- GTEC N/A
- GRCE N/A
- EPS
- GTEC N/A
- GRCE N/A
- Revenue
- GTEC $87,352,614.00
- GRCE N/A
- Revenue This Year
- GTEC N/A
- GRCE N/A
- Revenue Next Year
- GTEC $1.70
- GRCE N/A
- P/E Ratio
- GTEC N/A
- GRCE N/A
- Revenue Growth
- GTEC 0.76
- GRCE N/A
- 52 Week Low
- GTEC $1.25
- GRCE $2.07
- 52 Week High
- GTEC $2.94
- GRCE $4.97
- Technical
- Relative Strength Index (RSI)
- GTEC 33.66
- GRCE N/A
- Support Level
- GTEC $1.25
- GRCE N/A
- Resistance Level
- GTEC $1.38
- GRCE N/A
- Average True Range (ATR)
- GTEC 0.15
- GRCE 0.00
- MACD
- GTEC -0.01
- GRCE 0.00
- Stochastic Oscillator
- GTEC 14.75
- GRCE 0.00
About GTEC Greenland Technologies Holding Corporation
Greenland Technologies Holding Corp is a developer of quality solutions in the material handling industry. It is a transmission and drivetrain systems provider for material handling equipment such as forklift trucks for industrial and logistic applications. Geographically, the company has its presence in Domestic and International markets and earns majority of the revenue from Domestic Sales.
About GRCE GRACE THERAPEUTICS INC
Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage.